Use of calcium antagonists in hypertension

International Congress Series

Volumn 1237, Issue C, 2002, Pages 109-117

  Hernández Hernández, Rafael ^a   Velasco, Manuel ^b   Armas Hernández, Marı́a J ^a   Armas Padilla, Marı́a C ^a  

^a UNIVERSIDAD CENTROCCIDENTAL LISANDRO ALVARADO   (Venezuela)

^b UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

Author keywords

Calcium antagonists; Compliance; Dihydropyridines

Indexed keywords

EID: 10944220304     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0531-5131(02)00164-4     Document Type: Article

References (38)

1. Fleckenstein, A., History of calcium antagonists. Circ. Res.(suppl. 11), 1983, 1–16.
2. Singh, B.N., The mechanism of action of calcium antagonist relative to their clinical application. Br. J. Clin. Pharmacol. 21:suppl. 2 (1986), 109–122.
3. Godfraind, T., Salomone, S., Calcium antagonists and endothelial function: focus on nitric oxide and endothelin. Cardiovasc. Drug Ther. 10 (1996), 439–446.
4. Hernández-Hernández, R., Armas de Hernández, M.J., Armas Padilla, M.C., et al. Farmacologı́a Clı́nica de los calcio antagonistas en la hipertensión arterial. Bol. Med. Postgrad. 10:2 (1994), 127–138.
5. Donnelly, R., Elliott, H.L., Meredith, P.A., et al. Nifedipine: individual responses and concentration-effect relationship. Hypertension 12 (1988), 443–449.
6. Weir, M.R., Weder, A., for the MIST Study Group. Influence of race and dietary salt on blood pressure responses in salt-sensitive hypertensives. Am. J. Hypertens., 10, 1997, 19A (Abstract).
7. McCarron, D.A., Weder, A.B., Egan, B.M., Krishna, G.G., et al. Blood pressure and metabolic responses to moderate salt restriction in isradipine-treated hypertensive patients. Am. J. Hypertens. 10 (1997), 68–76.
8. Cubeddu, L.X., Aranda, J., Singh, B., Klein, M., Brachfeld, J., Freis, E., Roman, J., Eades, T., Comparison of verapamil and propranolol for the initial treatment of hypertension: racial differences in response. JAMA 256 (1986), 2214–2221.
9. Brown, M.J., Palmer, C.R., Castainge, A., et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a Goal in the Hypertension Treatment (INSIGHT). Lancet 356 (2000), 366–372.
10. Bond, M.G., Mercuri, M., Potential modification of plaque behavior through the European lacidipine study on atherosclerosis. J. Cardiovasc. Pharmacol. 25:suppl. 3 (1995), S11–S16.
11. Halperin, A., Cubeddu, L.X., Role of calcium channel blockers in the treatment of hypertension. Am. Heart J. 111 (1986), 363–382.
12. Lee, C.R., Bryson, H.M., Lacidipine: a review of its pharmacodynamic and pharmacokinetics properties and therapeutic potential in the treatment of hypertension. Drugs 48 (1996), 274–296.
13. Leenen, F.H., Ruzicka, M., Huang, B.S., Central sympatho-inhibitory effects of calcium channel blockers. Curr. Hypertens. Rep. 3:4 (2001), 314–321.
14. Opie, L.H., Yusuf, S., Kubler, W., Current status of safety and efficacy of calcium channel blockers in cardiovascular disease: a critical analysis based on 100 studies. Prog. Cardiovasc. Dis. 43 (2000), 171–196.
15. Psaty, B.M., Heckbert, S.R., Koepsell, T.D., Siscovick, D.S., Raghunathan, T.E., Weiss, N.S., Rosendaal, F.R., Lemaitre, R.N., Smith, N.L., Wahl, P.W., et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 274 (1995), 620–625.
16. Pahor, M., Guralnik, J.M., Corti, M., Foley, D.J., Carbonin, P., Havlik, R.J., Long-term survival and use of antihypertensive medications in older persons. J. Am. Geriatr. Soc. 43 (1995), 1191–1197.
17. Pahor, M., Psaty, B.M., Alderman, M.H., Applegate, W.B., Williamson, J.D., Cavazzini, C., Furberg, C.D., Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 356 (2000), 1949–1954.
18. Neal, B., et al., Blood Pressure Lowering Treatment Trialist's Collaboration. Effects of ACE inhibitors, calcium antagonists and other blood pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Blood Pressure Lowering Treatment Trialist's Collaboration. Lancet 356 (2000), 1955–1964.
19. Soltero, I., Calcium channel blockers: do they have pleiotropic effects on atherosclerosis?. J. Hum. Hypertens. 14:suppl. 1 (2000), S96–S99.
20. Hernández-Hernández, R., Armas-Hernández, M.J., Velasco, M., Armas-Padilla, M.C., Carvajal, A.R., Calcium channel blockers: their platelet actions. Velasco, M., Hernández, R., (eds.) New Advances in Cardiovascular Physiology and Pharmacology International Congress Series, vol. 1184, 1988, Elsevier, Amsterdam, 59–65.
21. Hernández Hernández, R., Armas Padilla, M.C., Velasco, M., Carvajal, A.R., Armas-Hernandez, M.J., Guerrero-Pajuelo, J., Pacheco, B., Effects of amlodipine and enalapril on platelet function in patients with mild to moderate hypertension. Int. J. Clin. Pharmacol., Ther. Toxicol. 37 (1999), 323–331.
22. Hernández-Hernández, R., The pharmacokinetics of calcium antagonists that matter for practice. Reyes, A.J., Maranhao, M.F.C., (eds.) Cardiovascular Pharmacotherapy, 2000, Monduzzi, Bologna, 287–291.
23. Krakoff, L.R., Bravo, E.L., Tuck, M.L., Friedman, C.P., The Modern Approach to the Treatment of Hypertension (MATH) Study Group. Nifedipine gastrointestinal therapeutic system in the treatment of hypertension. Results of a multicenter trial. Am. J. Hypertens. 3 (1990), 318S–325S.
24. Velasco, M., et al., for the LASTLHY group. Late decrease in body weight during antihypertensive treatment with fixed doses of calcium antagonists. J. Am. Coll. Cardiol., 31, 1998, 63C (abstract).
25. Hernández-Hernández, R., Armas-Hernández, M.J., Armas Padilla, M.C., Carvajal, A.R., Guerrero, J., The effects of missing a dose of enalapril versus amlodipine on ambulatory blood pressure. Blood Pressure Monit. 1 (1996), 121–126.
26. Lopes, A.A., Hornbuckle, K., James, S.A., Port, F.K., The joint effects of race and age on the risk of end-stage renal disease attributed to hypertension. Am. J. Kidney Dis. 24 (1994), 554–560.
27. Lopes, A.A., Port, F.K., James, S.A., Agodoa, L., The excess risk of treated end-stage renal disease in blacks in the United States. J. Am. Soc. Nephrol. 3 (1993), 1961–1971.
28. Lopes, A.A., Raça e hipertensão arterial. Rev. Bras. Hipertens. 3 (1996), 153–162.
29. Lopes, A.A., Port, F.K., Differences in the patterns of age-specific black/white comparisons between end-stage renal diseases attributed and not attributed to diabetes. Am. J. Kidney Dis. 25 (1995), 714–721.
30. Materson, B.J., Reda, D.J., Cushman, W.C., Department of Veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am. J. Hypertens. 8 (1995), 189–192.
31. Alcocer, L., Reyes, A.J., Antihypertensive treatment with diuretics in elderly patients. Reyes, A.J., (eds.) Diuretics in Hypertension and in Heart Failure Progress in Pharmacology and Clinical Pharmacology, vol. 10/3, 1995, Gustav Fischer, Stuttgart, 105–118.
32. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265 (1991), 3255–3264.
33. Fagard, R.H., Staessen, J.A., Treatment of isolated systolic hypertension in the elderly: the Syst-Eur trial. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Clin. Exp. Hypertens. 21:5–6 (1999), 491–497.
34. Moronde, R.F., Chan, L.S., Larsen, F.J., et al. Underutilization of antihypertensive drugs and associated hospitalization. Med. Care 27 (1989), 1159–1166.
35. Psaty, B.M., Koepsell, T.D., Wagner, E.D., et al. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA 263 (1990), 1653–1657.
36. Rudd, P., Partial compliance: implication for clinical practice. J. Cardiovasc. Pharmacol. 22:suppl. A (1993), S1–S5.
37. Leenen, F.H.H., Fourney, A., Notman, G., Tanner, J., Persistence of antihypertensive effect after “missed doses” of calcium antagonist with long (amlodipine) vs. short (diltiazem) elimination half-life. Br. J. Clin. Pharmacol. 41 (1996), 83–88.
38. Hernández-Hernández, R., Collina-Chourio, J.A., Armas-Padilla, M.C., López, L., Álvarez, M., Pacheco, B., Comparative effects of amlodipine and nifedipine GITS during treatment and after missing two doses. Blood Pressure Monit. 6:1 (2001), 47–57.